Leading Diabetes Association Grants First Continuing Education (CE)
Symposium on Chromium and Insulin Resistance
Wednesday, August 11, 2004, Nutrition 21, Inc. (NXXI) – A new scientific symposium on the role of chromium in insulin resistance was presented today at the Annual Meeting of the American Association of Diabetes Educators (AADE) in Indianapolis, as part of the organization’s Continuing Education (CE) program for diabetes educators. William Cefalu, MD, Chief of Nutrition at Pennington BioMedical Research Laboratory, New Orleans, LA, presented the body of evidence supporting the role of the essential mineral chromium in insulin function. Anne Daly, MS, RD, BC-ADM, CDE, Director of Nutrition & Diabetes Education at the Springfield Diabetes & Endocrinology Clinic, followed with a review of the clinical applications of chromium picolinate as an adjunct nutritional therapy in people with type 2 diabetes.
Program topics covered over 30 years of laboratory and clinical research, including:
o Chromium is an essential mineral required for normal insulin function and metabolism; it appears to potentiate the action of insulin to stimulate glucose transport into cells.
o Chromium can enhance the activity of key intracellular enzymes to improve glucose metabolism.
o An inverse relationship exists between chromium status and insulin-related diseases.
o Nutritional supplementation with chromium, especially in the form of chromium picolinate, enhances insulin sensitivity and reduces elevated blood glucose levels in people with insulin resistance and type 2 diabetes.
“We are pleased that AADE has recognized the significant body of evidence showing that chromium supplementation can improve insulin function and glucose metabolism in people with insulin resistance and diabetes. By granting continuing education credit for this important Symposium, the AADE has taken a leading role in educating healthcare professionals about these critical findings,” said Gail Montgomery, President and CEO, Nutrition 21, which supported the Symposium through an educational grant.
“Our ability to offer new proprietary chromium-based therapies for diabetes management will enable the healthcare community to cost-effectively improve patient care for millions of people with diabetes.” Diabetes educators are health professionals -- nurses, dietitians, pharmacists, exercise specialists, doctors, and social workers -- who specialize in the treatment of people with diabetes.
“In coping with diabetes, tight blood glucose must be the top priority; strategies for achieving this outcome include healthy eating, exercise, monitoring, and in some cases medications,” commented Anne Daly. “The growing body of clinical evidence showing Diachrome, Nutrition 21’s patented nutritional supplement which includes chromium picolinate, can significantly improve blood glucose control makes it a strong candidate for inclusion in diabetes treatment care plans.” No significant adverse side effects have been reported in studies using Diachrome, even with other medications.
There are 18.2 million people in the United States who have diabetes. Complications of poor blood glucose control in people with type 2 diabetes include heart disease and stroke, blindness, kidney damage and amputation (www.diabetes.org).
About Nutrition 21, Inc.
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The company markets Chromax® chromium picolinate, which is the most-studied form of the essential mineral chromium. Nutrition 21 also developed Diachrome®, which is available through diabetes educators or at www.diachrome.com. Nutrition 21 holds 35 patents for nutrition products, 22 for chromium compounds and their uses. More information is available at www.nutrition21.com. Following the conference, diabetes educators can still obtain credits by visiting Nutrition 21’s website.